Understanding factors affecting prostate cancer progression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to identify the clinical, genetic, and environmental factors that influence the progression of prostate cancer. By building two prospective cohorts in Guadeloupe and Rennes, the study will collect data through structured questionnaires and biological samples from patients diagnosed with prostate cancer. The goal is to understand why some cases are indolent while others are aggressive, taking into account the patients' ethno-geographic backgrounds and various risk factors. This knowledge could help tailor treatment and prevention strategies for high-risk populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Inclusion criteria:

Adult patients with incident case of prostate cancer Patient consulting the University Hospital of Guadeloupe or the University Hospital of Rennes Patient who resides in the departments of Guadeloupe or Martinique or the community of Saint-Martin or in Britany Patient affiliated or beneficiary of the social security signed consent

Exclusion Criteria:

Physical or mental health judjed by the investigator as precluding participation in the research Protected adults (guardianship, curatorship, safeguard of justice).

Where it's running

• CHU of Guadeloupe
  Pointe-à-Pitre, Guadeloupe, Guadeloupe Recruiting
• CHU of Rennes
  Rennes, Ille-et-Vilaine, France Not yet recruiting

Study contacts

• Study coordinator: Valérie HAMONY-SOTER
• Email: valerie.soter@chu-guadeloupe.fr
• Phone: +590 590 93 46 77

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pluvicto real-world use in metastatic castration-resistant prostate cancer

  This real-world study tests how well Pluvicto works in men with metastatic castration-resistant prostate cancer in the US and Germany.

  Recruiting Novartis · East Hanover, New Jersey · NCT07697989

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• TriAdeno and N-803 vaccine in early prostate cancer on active surveillance

  A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07574541

• LM-302 with tislelizumab plus chemotherapy for stomach and gastroesophageal junction cancer

  This phase 3 study tests whether LM-302 added to tislelizumab is better or safer than tislelizumab with chemotherapy in patients with newly diagnosed, unresectable or metastatic stomach/GEJ adenocarcinoma that express CLDN18.2.

  Recruiting Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 105 other locations · NCT07385703

• Relacorilant with nab-paclitaxel and gemcitabine for metastatic pancreatic adenocarcinoma

  This trial tests whether adding relacorilant to standard chemotherapy (nab-paclitaxel plus gemcitabine) helps people with previously untreated metastatic pancreatic adenocarcinoma.

  Recruiting at 19 sites Phase 2 Corcept Therapeutics · Scottsdale, Arizona and 19 other locations · NCT07259317

• Vepugratinib with enfortumab vedotin and pembrolizumab for FGFR3‑altered advanced urothelial cancer

  This trial tests whether adding vepugratinib to enfortumab vedotin and pembrolizumab helps people with advanced or metastatic urothelial (bladder) cancer who have an FGFR3 genetic change, compared with placebo.

  Recruiting at 129 sites Phase 3 Eli Lilly and Company · Tucson, Arizona and 275 other locations · NCT07218380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.